Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41

Benzinga Newsdesk www.benzinga.com Positive 82.9%

Neg 0% Neu 0% Pos 82.9%

Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $34 to $41.